Company profile: Plexxikon
1.1 - Company Overview
Company description
- Provider of small molecule pharmaceuticals focused on discovering and developing therapies for human diseases. Portfolio includes Zelboraf for BRAF V600E–mutant skin cancer, Turalio for tenosynovial giant cell tumor (TGCT), and personalized medicines. Pipeline candidates include PLX204 for diabetes, PLX4032 for melanoma and colorectal cancer, and PLX5568 kinase inhibitors for pain and polycystic kidney disease.
Products and services
- Personalized Medicines: Plexxikon develops custom-engineered small molecule pharmaceuticals tailored to individual patient characteristics, focused on treating specific human diseases with individualized design and patient-specific targeting
- Turalio: A small molecule drug engineered to treat tenosynovial giant cell tumor (TGCT), a rare and debilitating condition, addressing patients with this defined diagnosis
- Zelboraf: A mutation-specific pharmaceutical used in the treatment of certain types of skin cancer, specifically targeting the BRAF V600E mutation to address this genetically defined cancer subset
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Plexxikon
TargeGen
HQ: United States
Website
- Description: Provider of vascular biology-focused small molecule kinase inhibitors targeting vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation, offering treatments for human diseases such as heart attack, cancer, and eye diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TargeGen company profile →
Vicore Pharma
HQ: Sweden
Website
- Description: Provider of pharmaceuticals for severe lung disorders, developing drugs acting through the angiotensin II type 2 (AT2) receptor, including buloxibutid (C21), an orally available ATRAG in phase 2a for idiopathic pulmonary fibrosis (IPF) with orphan drug designation in the EU, and Almee, a digital therapeutic based on cognitive behavioral therapy to address the psychological impact of pulmonary fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vicore Pharma company profile →
4P Therapeutics
HQ: United States
Website
- Description: Provider of research and development of novel drug delivery technologies and therapeutics, developing pharmaceutical products from pre-clinical testing to clinical manufacturing, with a focus on meeting the needs of patients, physicians and payers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4P Therapeutics company profile →
Syntaxin
HQ: United Kingdom
Website
- Description: Provider of bacterial-based protein therapeutics for neurological, inflammatory and endocrine diseases, leveraging a proprietary technology platform to engineer bacterial proteins via domain substitution.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syntaxin company profile →
Senda Biosciences
HQ: United States
Website
- Description: Provider of a therapeutics platform leveraging insights into molecular connections between humans, offering Endless RNA (eRNA) to program proteins inside the body with long-lasting expression, Natural NanoParticle (NNP) technology with nanoparticles derived from nature for targeted delivery of biomolecules into human cells, and AI-driven integrative design of RNA medicines for oncology and rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Senda Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Plexxikon
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Plexxikon
2.2 - Growth funds investing in similar companies to Plexxikon
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Plexxikon
4.2 - Public trading comparable groups for Plexxikon
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →